* Pediarix. The U diet and Drug Ad...

* Pediarix. The U diet and Drug Administration (FDA) has approved Pediarix, a combination vaccine that contains diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (DTaP), hepatitis B vaccine (recombinant), and inactivated poliovirus vaccine (IPV) for administration as single in kind intramuscular injection.

DTaP vaccine, hepatitis B vaccine, and IPV are available in the United States as separate vaccines. A hepatitis B (recombinant) and Haemophilus influenzae emblem b combination vaccine is also available in the United States.

Pediarix is commited for administration as a three-dose primary series to infants at approximately pair four, and six months of age. When DTaP, hepatitis B and IPV vaccines are administered separately in the same time frame, infants receive nine injections. Pediarix should not be given to infants before the age of six weeks, and it is not indicated for infants born to mothers who are infected with hepatitis B or whose hepatitis B status is unknown. of that kind infants should receive hepatitis B vaccine shortly after birth and consummated their immunization according to a particular schedule.

The in the greatest degree frequently reported adverse reactions to Pediarix in clinical studies were local injection site reactions (pain, rednes swelling), ferment and fussiness. In clinical studies, febrile affection occurred more frequently after administration of Pediarix than separately administered licensed vaccines.

COPYRIGHT 2003 American Academy of Family Physicians

COPYRIGHT 2003 Gale Group